Yoon-Koo Kang
Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.
Yoon-Koo Kang is a senior gastrointestinal oncologist at Asan Medical Center whose trials established nivolumab in late-line gastric cancer in Asia and zolbetuximab as the first Claudin 18.2-directed therapy; he also led imatinib and other GIST studies.
Pages like this
not linked directly; found by shared links- PersonMin-Hee Ryu
Shares SPOTLIGHT & GLOW, Asan Medical Center, Zolbetuximab, Claudin 18.2.
- IdeaBiomarker-directed first-line quadruplets in gastric cancer
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Nivolumab.
- PersonKohei Shitara
Shares SPOTLIGHT & GLOW, Zolbetuximab, SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer, Claudin 18.2.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares SPOTLIGHT & GLOW, Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).
- PersonSun Young Rha
Shares SPOTLIGHT & GLOW, Zolbetuximab, Gastric & gastro-oesophageal junction cancer.
- PersonJeeyun Lee
Shares Zolbetuximab, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.
- PersonCharles D. Blanke
Shares KIT, Imatinib, Sarcomas (soft tissue, bone, GIST).